# Phase I Clinical Study of SHR-5495 in the Treatment of Patients With Advanced Malignant Tumors

> **NCT06059508** · PHASE1 · UNKNOWN · sponsor: **Suzhou Suncadia Biopharmaceuticals Co., Ltd.** · enrollment: 100 (estimated)

## Conditions studied

- Advanced Malignant Tumor

## Interventions

- **DRUG:** SHR-5495 for injection

## Key facts

- **NCT ID:** NCT06059508
- **Lead sponsor:** Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-10-25
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2023-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06059508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06059508, "Phase I Clinical Study of SHR-5495 in the Treatment of Patients With Advanced Malignant Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06059508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*